MetaCap

Lakefront Biotherapeutics ADR (LKFT)

NASDAQ: LKFTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

33.31-0.08 (-0.24%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LKFT stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
$13.94
52-week range
25.68 – 36.24
Day range
33.25 – 33.85
Volume / Avg
162.49K / 280.49K
Beta
—

52-week range

$25.68$36.24

LKFT stock today

On Nov 20, LKFT ended the session at $33.31, shedding $0.08 (0.24%), versus the S&P 500's 3.70% decline. Shares are 8.1% below their 52-week high of $36.24, set on Feb 24, 2026 and 29.7% above the 52-week low of $25.68, in the middle of the past year's range. LKFT is up 1.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 8.6%.

At 2.4x trailing earnings, Lakefront Biotherapeutics trades below the peer-group median of 15.3x.

Summary generated from market data by MetaCap's automated system. Methodology

About Lakefront Biotherapeutics

Company profile

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Henry O. Gosebruch
Headquarters
Mechelen
Employees
196
IPO year
2015

Analyst forecast

Forecast

Consensus (6 analysts)

hold

Avg. price target

$30.85-7.39%

  • Strong buy 1
  • Buy 1
  • Hold 3
  • Sell 1
  • Strong sell 0

Target range

Low $20.93High $44.67

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

LKFT news

All LKFT news

Lakefront Biotherapeutics peers

Health Care sector
LKFT peer companies
CompanyPrice% ChgMarket capCompare
NAMSNewAmsterdam Pharma Company N.V.18.41-5.64%$2.21Bvs LKFT
PRGOPerrigo Company plc15.94-0.62%$2.21Bvs LKFT
PHVSPharvaris N.V.31.28-1.20%$2.21Bvs LKFT
RCUSArcus Biosciences Inc.15.62-1.01%$2.25Bvs LKFT
HCMHUTCHMED (China) Limited ADR13.22-1.71%$2.30Bvs LKFT
PVLAPalvella Therapeutics Inc.142.85-2.00%$2.09Bvs LKFT
PBHPrestige Consumer Healthcare Inc.49.63+0.06%$2.35Bvs LKFT
AUPHAurinia Pharmaceuticals Inc14.70-1.28%$1.97Bvs LKFT

Indexes, lists and sector

Lakefront Biotherapeutics stock FAQ

What is Lakefront Biotherapeutics's stock price today?

LKFT last traded at $33.31 as of Nov 20, 4:00 PM EST, down 0.24% on the day. Prices are delayed at least 15 minutes.

What is LKFT's P/E ratio?

LKFT trades at a trailing P/E ratio of 2.39, compared with a median of 15.3 for its closest peers.

Who is Lakefront Biotherapeutics's CEO?

Mr. Henry O. Gosebruch is the chief executive officer of Lakefront Biotherapeutics ADR, which has about 196 employees.

What is the LKFT 52-week high?

The 52-week high for LKFT is $36.24 and the 52-week low is $25.68. The stock is currently 8.1% below its high.

Compare LKFT